Polyrizon Ltd.: Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...
The Manila Times19h
Meridianbet Expands B2B Operations into Nigeria, Entering a Regulated $2 Billion Betting Market
The official launch of Meridianbet.ng marks a strategic expansion into a market worth over $2 billion, according to the ...
Polyrizon launches preclinical studies for intranasal naloxone
Polyrizon (PLRZ) previously announced the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment.